Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 584

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 584
---
 not generated any revenue from product sales, and do not know when, or if, Kineta will generate any revenue from product sales. Kineta does not expect to generate any revenue from product sales unless and until Kineta obtains regulatory approval of and commercialize any of Kineta’s product candidates. At the same time, Kineta expects Kineta’s expenses to increase in connection with Kineta’s ongoing development activities, particularly as Kineta continues the research, development and clinical trials of, and seeks regulatory approval for, Kineta’s product candidates. In addition, subject to obtaining regulatory approval of any of Kineta’s product candidates, Kineta anticipates that Kineta will need substantial additional funding in connection with Kineta’s continuing operations. Kineta plans to continue to fund Kineta’s operations and capital requirements through equity and/or debt financing, but there are no assurances that Kineta will be able to raise sufficient amounts of funding in the future on acceptable terms, or at all. Kineta’s future funding requirements will depend on many factors, including:

| • |     | the progress, timing, scope, results and costs of the clinical trials of VISTA and preclinical studies or clinical trials of other potential product candidates Kineta may choose to pursue in the future, including the ability to enroll patients in a timely manner for Kineta’s clinical trials; |

| • |     | the costs and timing of obtaining clinical and commercial supplies and validating the commercial manufacturing process for VISTA and any other product candidates Kineta may identify and develop; |

| • |     | the cost, timing and outcomes of regulatory approvals; |

| • |     | the timing and amount of any milestone, royalty or other payments Kineta is required to make pursuant to current or any future collaboration or license agreements; |

378

| • |     | costs of acquiring or in-licensing other product candidates and technologies; |

| • |     | the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; |

| • |     | the costs associated with attracting, hiring and retaining existing and additional qualified personnel as Kineta’s business grows; |

| • |     | efforts to enhance operational systems and hire additional personnel to satisfy Kineta’s obligations as a public company, including enhanced internal controls over financial reporting; and |

| • |     | the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. |

As of September 30, 2024, Kineta had cash of $1.9